Previous 10 | Next 10 |
home / stock / crsp / crsp articles
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 5.73% on an annualized basis producing an average annual ret...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Crispr Therapeutics (NASDAQ:CRSP) shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeuti...
ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creatin...
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 4.96% on an annualized basis producing an average annual ret...
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 1.56% on an annualized basis producing an average annual ret...
On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling a substantial portion of its stake in DraftKings Inc (NASDAQ:DKNG). T...
Tuesday, the FDA approved CRISPR Therapeutics AG’s (NASDAQ:CRSP)/Vertex Pharmaceutical Incorporated’s (NASDAQ:VRTX) Casg...
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units....
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website:
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...